120 related articles for article (PubMed ID: 3760382)
1. Gated blood pool scintigraphic monitoring of doxorubicin cardiomyopathy: comparison of camera and computerized probe results in 101 patients.
Strashun AM; Goldsmith SJ; Horowitz SF
J Am Coll Cardiol; 1986 Nov; 8(5):1082-7. PubMed ID: 3760382
[TBL] [Abstract][Full Text] [Related]
2. Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
Schwartz RG; McKenzie WB; Alexander J; Sager P; D'Souza A; Manatunga A; Schwartz PE; Berger HJ; Setaro J; Surkin L
Am J Med; 1987 Jun; 82(6):1109-18. PubMed ID: 3605130
[TBL] [Abstract][Full Text] [Related]
3. Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
Speyer JL; Green MD; Dubin N; Blum RH; Wernz JC; Roses D; Sanger J; Muggia FM
Am J Med; 1985 Apr; 78(4):555-63. PubMed ID: 3838618
[TBL] [Abstract][Full Text] [Related]
4. Serial radionuclide assessment of doxorubicin cardiotoxicity in cancer patients with abnormal baseline resting left ventricular performance.
Choi BW; Berger HJ; Schwartz PE; Alexander J; Wackers FJ; Gottschalk A; Zaret BL
Am Heart J; 1983 Oct; 106(4 Pt 1):638-43. PubMed ID: 6613807
[TBL] [Abstract][Full Text] [Related]
5. Early decline in left ventricular ejection fraction predicts doxorubicin cardiotoxicity in lymphoma patients.
Nousiainen T; Jantunen E; Vanninen E; Hartikainen J
Br J Cancer; 2002 Jun; 86(11):1697-700. PubMed ID: 12087452
[TBL] [Abstract][Full Text] [Related]
6. Detection of doxorubicin cardiotoxicity in patients with sarcomas by indium-111-antimyosin monoclonal antibody studies.
Carrió I; Lopez-Pousa A; Estorch M; Duncker D; Berná L; Torres G; de Andrés L
J Nucl Med; 1993 Sep; 34(9):1503-7. PubMed ID: 8355070
[TBL] [Abstract][Full Text] [Related]
7. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.
Alexander J; Dainiak N; Berger HJ; Goldman L; Johnstone D; Reduto L; Duffy T; Schwartz P; Gottschalk A; Zaret BL
N Engl J Med; 1979 Feb; 300(6):278-83. PubMed ID: 759880
[TBL] [Abstract][Full Text] [Related]
8. Comparative analysis of noninvasive cardiac parameters in the detection and evaluation of adriamycin cardiotoxicity.
Shuman RD; Ettinger DS; Abeloff MD; Livengood SV; Fortuin NJ
Johns Hopkins Med J; 1981 Aug; 149(2):57-63. PubMed ID: 7253365
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era.
Mitani I; Jain D; Joska TM; Burtness B; Zaret BL
J Nucl Cardiol; 2003; 10(2):132-9. PubMed ID: 12673177
[TBL] [Abstract][Full Text] [Related]
10. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
Skubitz KM; Blaes AH; Konety SH; Francis GS
Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
[TBL] [Abstract][Full Text] [Related]
11. Clinical and economic impact of multiple gated acquisition scan monitoring during anthracycline therapy.
Shureiqi I; Cantor SB; Lippman SM; Brenner DE; Chernew ME; Fendrick AM
Br J Cancer; 2002 Jan; 86(2):226-32. PubMed ID: 11870511
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of doxorubicin-induced cardiomyopathy resulting from postsurgical adjuvant treatment of patients with soft tissue sarcomas.
Dresdale A; Bonow RO; Wesley R; Palmeri ST; Barr L; Mathison D; D'Angelo T; Rosenberg SA
Cancer; 1983 Jul; 52(1):51-60. PubMed ID: 6850545
[TBL] [Abstract][Full Text] [Related]
13. Selective right ventricular dysfunction following doxorubicin therapy.
Sperber AD; Cantor AA; Biran H; Keynan A
Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of doxorubicin cardiotoxicity by rest and exercise radionuclide angiography.
Palmeri ST; Bonow RO; Myers CE; Seipp C; Jenkins J; Green MV; Bacharach SL; Rosenberg SA
Am J Cardiol; 1986 Sep; 58(7):607-13. PubMed ID: 3751931
[TBL] [Abstract][Full Text] [Related]
15. Prediction of the left ventricular ejection fraction response to doxorubicin using a multiple linear regression model.
Rabinovitch M; Suissa S; Stern J; Adam J; Mettauer B; Boileau G; Elstein J; Rouleau J
Can J Cardiol; 1989; 5(8):382-8. PubMed ID: 2605548
[TBL] [Abstract][Full Text] [Related]
16. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography.
Villani F; Meazza R; Materazzo C
Anticancer Res; 2006; 26(1B):797-801. PubMed ID: 16739356
[TBL] [Abstract][Full Text] [Related]
17. Detection of early anthracycline cardiotoxicity by monitoring the peak filling rate.
Ganz WI; Sridhar KS; Forness TJ
Am J Clin Oncol; 1993 Apr; 16(2):109-12. PubMed ID: 8452100
[TBL] [Abstract][Full Text] [Related]
18. High incidence of adriamycin cardiotoxicity in children even at low cumulative doses: role of radionuclide cardiac angiography.
Agarwala S; Kumar R; Bhatnagar V; Bajpai M; Gupta DK; Mitra DK
J Pediatr Surg; 2000 Dec; 35(12):1786-9. PubMed ID: 11101737
[TBL] [Abstract][Full Text] [Related]
19. Radionuclide ejection fraction in doxorubicin cardiotoxicity.
Morgan GW; McIlveen BM; Freedman A; Murray IP
Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982
[TBL] [Abstract][Full Text] [Related]
20. Assessing adriamycin-induced early cardiotoxicity by estimating left ventricular ejection fraction using technetium-99m multiple-gated acquisition scan and echocardiography.
Fatima N; Zaman MU; Hashmi A; Kamal S; Hameed A
Nucl Med Commun; 2011 May; 32(5):381-5. PubMed ID: 21346663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
